{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:54:00Z","timestamp":1761274440870,"version":"build-2065373602"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011770","name":"Skaggs Institute for Chemical Biology, Scripps Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.cbpa.2021.102105","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T01:58:03Z","timestamp":1639965483000},"page":"102105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Development of effective therapeutics for polysubstance use disorders"],"prefix":"10.1016","volume":"66","author":[{"given":"Jinny Claire","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6759-4227","authenticated-orcid":false,"given":"Kim D.","family":"Janda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"first-page":"8","year":"2020","series-title":"Highlights from NDEWS sentinel community site 2020 reports","key":"10.1016\/j.cbpa.2021.102105_bib1"},{"key":"10.1016\/j.cbpa.2021.102105_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12954-015-0088-4","article-title":"Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada","volume":"12","author":"Amlani","year":"2015","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.cbpa.2021.102105_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/YCO.0000000000000069","article-title":"Polysubstance use: diagnostic challenges, patterns of use and health","volume":"27","author":"Connor","year":"2014","journal-title":"Curr Opin Psychiatr"},{"key":"10.1016\/j.cbpa.2021.102105_bib4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/j.pain.0000000000000892","article-title":"Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data","volume":"158","author":"Morley","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.cbpa.2021.102105_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12954-018-0240-z","article-title":"Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD","volume":"15","author":"Park","year":"2018","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.cbpa.2021.102105_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.cbpa.2021.102105_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.cbpa.2021.102105_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","article-title":"Polysubstance use: a broader understanding of substance use during the opioid crisis","volume":"110","author":"Cicero","year":"2020","journal-title":"Am J Publ Health"},{"key":"10.1016\/j.cbpa.2021.102105_sref9","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: drug testing in 2020","volume":"24","author":"Niles","year":"2021","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.cbpa.2021.102105_bib10","doi-asserted-by":"crossref","first-page":"e192851","DOI":"10.1001\/jamanetworkopen.2019.2851","article-title":"Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine","volume":"2","author":"LaRue","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.cbpa.2021.102105_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1176\/appi.prcp.20180006","article-title":"Pharmacological and behavioral treatment of opioid use disorder","volume":"1","author":"Sofuoglu","year":"2019","journal-title":"Psychiat Res Clin Pract"},{"key":"10.1016\/j.cbpa.2021.102105_bib12","series-title":"Handbook of office-based buprenorphine treatment of opioid dependence","first-page":"191","author":"Stankiewicz","year":"2017"},{"key":"10.1016\/j.cbpa.2021.102105_sref13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1196\/annals.1441.027","article-title":"Substance abuse vaccines","volume":"1141","author":"Orson","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cbpa.2021.102105_bib14","doi-asserted-by":"crossref","first-page":"108060","DOI":"10.1016\/j.drugalcdep.2020.108060","article-title":"Non-pharmacological interventions for methamphetamine use disorder: a systematic review","volume":"212","author":"AshaRani","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.cbpa.2021.102105_bib15","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1016\/j.vaccine.2014.07.085","article-title":"Adjuvants for vaccines to drugs of abuse and addiction","volume":"32","author":"Alving","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2021.102105_bib16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/bcp.12115","article-title":"Vaccines against stimulants: cocaine and MA","volume":"77","author":"Kosten","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cbpa.2021.102105_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4161\/hv.5.4.7456","article-title":"Development of active and passive human vaccines to treat methamphetamine addiction","volume":"5","author":"Gentry","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.cbpa.2021.102105_bib18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMra1508490","article-title":"Relationship between nonmedical prescription-opioid use and heroin use","volume":"374","author":"Compton","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cbpa.2021.102105_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2005.06.009","article-title":"Immunotherapy for the treatment of drug abuse","volume":"108","author":"Kosten","year":"2005","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.cbpa.2021.102105_bib20","first-page":"263","article-title":"Chapter eight - animal models and the development of vaccines to treat substance use disorders","volume":"vol. 126","author":"Ohia-Nwoko","year":"2016"},{"year":"2013","series-title":"The specificity of serological reactions","author":"Landsteiner","key":"10.1016\/j.cbpa.2021.102105_bib21"},{"key":"10.1016\/j.cbpa.2021.102105_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pbb.2009.01.015","article-title":"Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence","volume":"92","author":"Moreno","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.cbpa.2021.102105_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/156652313804806552","article-title":"The development of antibody-based immunotherapy for methamphetamine abuse: immunization, and virus-mediated gene transfer approaches","volume":"13","author":"Chen","year":"2013","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.cbpa.2021.102105_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/icb.2009.17","article-title":"Anti-drug vaccines to treat substance abuse","volume":"87","author":"Kinsey","year":"2009","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.cbpa.2021.102105_bib25","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cclet.2020.10.038","article-title":"Synthesis and biological evaluation of a lipopeptide-based methamphetamine vaccine","volume":"32","author":"Liao","year":"2021","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.cbpa.2021.102105_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1567-5769(02)00260-6","article-title":"Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant","volume":"3","author":"Sanderson","year":"2003","journal-title":"Int Immunopharm"},{"key":"10.1016\/j.cbpa.2021.102105_bib27","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acschemneuro.5b00345","article-title":"Suppression of cocaine-evoked hyperactivity by self-adjuvanting and multivalent peptide nanofiber vaccines","volume":"7","author":"Rudra","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.cbpa.2021.102105_bib28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.cbpa.2021.102105_bib29","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1471-4159.2011.07502.x","article-title":"A\u00a0morphine\/heroin vaccine with new hapten design attenuates behavioral effects in rats","volume":"119","author":"Li","year":"2011","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.cbpa.2021.102105_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.jmedchem.7b01427","article-title":"A\u00a0stable heroin analogue that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse","volume":"61","author":"Sulima","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cbpa.2021.102105_bib31","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1021\/acs.molpharmaceut.7b00933","article-title":"Enhancing efficacy and stability of an antiheroin vaccine: examination of antinociception, opioid binding profile, and lethality","volume":"15","author":"Hwang","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cbpa.2021.102105_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-3565(25)30084-4","article-title":"Antibodies to fentanyl","volume":"192","author":"Henderson","year":"1975","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.cbpa.2021.102105_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/253565a0","article-title":"Prevention of the effects of fentanyl by immunological means","volume":"253","author":"Torten","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.cbpa.2021.102105_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A\u00a0fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J\u00a0Pharmacol Exp Therapeut"},{"key":"10.1016\/j.cbpa.2021.102105_sref35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1021\/acschembio.1c00026","article-title":"A\u00a0highly efficacious carfentanil vaccine that blunts opioid-induced antinociception and respiratory depression","volume":"16","author":"Eubanks","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cbpa.2021.102105_bib36","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.cbpa.2021.102105_bib37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.drudis.2019.07.009","article-title":"Immunotherapy for treating methamphetamine, heroin and cocaine use disorders","volume":"25","author":"Xiaoshan","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cbpa.2021.102105_sref38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1039\/D0CB00165A","article-title":"Immunopharmacotherapeutic advancements in addressing methamphetamine abuse","volume":"2","author":"Lee","year":"2021","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.cbpa.2021.102105_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0091-3057(99)00206-3","article-title":"A\u00a0nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats","volume":"65","author":"Pentel","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.cbpa.2021.102105_bib40","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1080\/03639045.2020.1820033","article-title":"Intranasal delivery of a nicotine vaccine candidate induces antibodies in mouse blood and lung mucosal secretions that specifically neutralize nicotine","volume":"46","author":"Alzhrani","year":"2020","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.cbpa.2021.102105_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/jacsau.0c00057","article-title":"Broadly neutralizing synthetic cannabinoid vaccines","volume":"1","author":"Lin","year":"2021","journal-title":"JACS Au"},{"key":"10.1016\/j.cbpa.2021.102105_bib42","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1021\/acschemneuro.1c00360","article-title":"Pharmacokinetic approach to combat the synthetic cannabinoid PB-22","volume":"12","author":"Lin","year":"2021","journal-title":"ACS Chem Neurosci"},{"year":"2005","series-title":"Efficacy and safety of nicotine-qbeta vaccine in smokers","key":"10.1016\/j.cbpa.2021.102105_bib43"},{"year":"2008","series-title":"Study of TA-NIC to assess the efficacy and safety of the vaccine as an aid to smoking cessation","key":"10.1016\/j.cbpa.2021.102105_bib44"},{"year":"2012","series-title":"Improving the efficacy of anti-nicotine immunotherapy","author":"Alexey","key":"10.1016\/j.cbpa.2021.102105_bib45"},{"year":"2006","series-title":"Safety and effectiveness of NicVAX in treating nicotine dependent individuals","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib46"},{"year":"2007","series-title":"Efficacy of NicVAX in smokers who want to quit smoking","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib47"},{"year":"2010","series-title":"Antibody and safety study of 6 doses of NicVAX in smokers","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib48"},{"year":"2011","series-title":"A\u00a0comparability study of the phase 3 lot and a single commercial lot of NicVAX in healthy adult smokers","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib49"},{"year":"2011","series-title":"A\u00a0follow-up study to assess long-term immunogenicity and safety of NicVAX\/placebo as an aid to smoking cessation","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib50"},{"year":"2011","series-title":"A\u00a0second study of NicVAX\/placebo as an aid for smoking cessation","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib51"},{"year":"2011","series-title":"NicVAX\/placebo as an aid for smoking cessation","author":"Nabi","key":"10.1016\/j.cbpa.2021.102105_bib52"},{"year":"2009","series-title":"Therapeutic cocaine vaccine: human laboratory study","key":"10.1016\/j.cbpa.2021.102105_bib53"},{"year":"2012","series-title":"Multisite controlled trial of cocaine vaccine","key":"10.1016\/j.cbpa.2021.102105_bib54"},{"key":"10.1016\/j.cbpa.2021.102105_bib55","unstructured":"InterveXion Therapeutics L: study of antibody for methamphetamine outpatient therapy, 2021."},{"key":"10.1016\/j.cbpa.2021.102105_bib56","unstructured":"New York State Psychiatric I, Clinilabs I: clinical trials of multivalent opioid vaccine components, 2023."},{"key":"10.1016\/j.cbpa.2021.102105_bib57","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cbpa.2021.102105_bib58","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acschemneuro.8b00079","article-title":"Efficacious vaccine against heroin contaminated with fentanyl","volume":"9","author":"Hwang","year":"2018","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.cbpa.2021.102105_bib59","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1021\/acsomega.8b01478","article-title":"Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: antinociceptive evaluation of fentanyl-contaminated heroin","volume":"3","author":"Hwang","year":"2018","journal-title":"ACS Omega"},{"issue":"Suppl 4","key":"10.1016\/j.cbpa.2021.102105_bib60","doi-asserted-by":"crossref","first-page":"S351","DOI":"10.1086\/322579","article-title":"Manufacturing issues with combining different antigens: a regulatory perspective","volume":"33","author":"Falk","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2021.102105_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin Vaccine Immunol : CVI"},{"key":"10.1016\/j.cbpa.2021.102105_sref62","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3762\/bjoc.15.100","article-title":"A\u00a0chemically contiguous hapten approach for a heroin\u2013fentanyl vaccine","volume":"15","author":"Natori","year":"2019","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.cbpa.2021.102105_sref63","doi-asserted-by":"crossref","first-page":"116225","DOI":"10.1016\/j.bmc.2021.116225","article-title":"Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin","volume":"41","author":"Park","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2021.102105_bib64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40263-020-00722-8","article-title":"Preclinical evaluation of vaccines to treat opioid use disorders: how close are we to a clinically viable therapeutic?","volume":"34","author":"Townsend","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.cbpa.2021.102105_sref65","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1021\/acschemneuro.0c00064","article-title":"Evaluation of a dual fentanyl\/heroin vaccine on the antinociceptive and reinforcing effects of a fentanyl\/heroin mixture in male and female rats","volume":"11","author":"Townsend","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.cbpa.2021.102105_bib66","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5501\/wjv.v4.i3.156","article-title":"Novel antigen delivery systems","volume":"4","author":"Trovato","year":"2015","journal-title":"World J Virol"},{"key":"10.1016\/j.cbpa.2021.102105_bib67","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fnins.2020.00569","article-title":"One is not enough: understanding and modeling polysubstance use","volume":"14","author":"Crummy","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.cbpa.2021.102105_bib68","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pnpbp.2015.11.004","article-title":"Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse","volume":"65","author":"Van Skike","year":"2016","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatr"},{"key":"10.1016\/j.cbpa.2021.102105_bib69","doi-asserted-by":"crossref","DOI":"10.1021\/acs.bioconjchem.1c00179","article-title":"Bivalent conjugate vaccine induces dual immunogenic response that attenuates heroin and fentanyl effects in mice","author":"Barrientos","year":"2021","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.cbpa.2021.102105_bib70","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0323-17.2017","article-title":"Heroin contaminated with fentanyl dramatically enhances brain hypoxia and induces brain hypothermia","volume":"4","author":"Solis","year":"2017","journal-title":"eNeuro"},{"key":"10.1016\/j.cbpa.2021.102105_bib71","first-page":"676","volume":"vol. 5","author":"Pearson","year":"2015"},{"key":"10.1016\/j.cbpa.2021.102105_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/jat\/bkx013","article-title":"A\u00a0cluster of fentanyl-laced heroin deaths in 2015 in Melbourne, Australia","volume":"41","author":"Rodda","year":"2017","journal-title":"J\u00a0Anal Toxicol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593121001447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593121001447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:48:44Z","timestamp":1761274124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593121001447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":72,"alternative-id":["S1367593121001447"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2021.102105","relation":{},"ISSN":["1367-5931"],"issn-type":[{"type":"print","value":"1367-5931"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of effective therapeutics for polysubstance use disorders","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2021.102105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102105"}}